Loading briefing details...
Loading briefing details...
News Abstract
By: NewsAbstract Editorial Team
Topic: Business
March 26, 2026
CD Bioparticles' new resins significantly enhance AAV vector purification for gene therapies and vaccines. Their alkali tolerance and reusability reduce costs and downtime, accelerating the production of safer, more effective biopharmaceuticals. This innovation is crucial for advancing next-generation medical treatments and ensuring industry compliance and sustainability.
NEW YORK, NY – March 26, 2026 – CD Bioparticles, a leader in life science solutions, proudly announces its new line of Alkali-Tolerant AAV Affinity Agarose Resins. Engineered for the biopharmaceutical industry, these high-capacity resins optimize Adeno-Associated Virus (AAV) vector purification, accelerating next-generation gene therapies and vaccines. This innovation directly addresses the critical need for high-quality AAV manufacturing.
These advanced resins enable efficient, scalable purification for diverse AAV vector subtypes, including AAV2, AAV5, AAV8, and AAV9. A key benefit is their exceptional alkaline stability and proven reusability for over 20 cycles, even with 0.1–0.5 M NaOH CIP washing. This durability extends resin lifespan, reduces operational downtime, and lowers per-batch costs, promoting sustainable and cost-efficient bioprocesses from research to industrial scale.
CD Bioparticles' new AAV affinity resins deliver high dynamic binding capacity, streamlining purification workflows. They ensure superior impurity removal, effectively depleting host cell proteins (HCP) and residual DNA. Fully compatible with standard bioprocess columns, these resins provide a robust solution for generating clinical GMP-grade AAV vectors, ensuring the safety, efficacy, and compliance of vital biopharmaceutical products.